Related references
Note: Only part of the references are listed.Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
Jeffrey A. Cohen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
The prevalence of MS in the United States A population-based estimate using health claims data
Mitchell T. Wallin et al.
NEUROLOGY (2019)
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis
Finja Schweitzer et al.
CURRENT OPINION IN NEUROLOGY (2019)
Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era
Satyam Arora et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis A Randomized Clinical Trial
Richard K. Burt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant
Jennifer C. Massey et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis
Peter J. Darlington et al.
FRONTIERS IN IMMUNOLOGY (2018)
Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist
John A. Snowden et al.
CLINICAL MEDICINE (2018)
Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions
Alessandra Musella et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Disease-modifying therapies for multiple sclerosis
Floriana De Angelis et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years
C. Martinez et al.
ANNALS OF HEMATOLOGY (2017)
Multiple sclerosis: Frequency, cost, and economic burden in the United States
Alex Y. Chen et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2017)
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Paolo A. Muraro et al.
NATURE REVIEWS NEUROLOGY (2017)
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Bonaventura Casanova et al.
NEUROLOGICAL SCIENCES (2017)
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
Richard A. Nash et al.
NEUROLOGY (2017)
Autologous hematopoietic stem cell transplantation in multiple sclerosis A meta-analysis
Maria Pia Sormani et al.
NEUROLOGY (2017)
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
Daniel M. Hartung
NEUROTHERAPEUTICS (2017)
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Paolo A. Muraro et al.
JAMA NEUROLOGY (2017)
Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation
F. G. Karnell et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Ankur Varma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Does ex vivo CD34+positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?
M. C. Oliveira et al.
BONE MARROW TRANSPLANTATION (2016)
Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis
Slawomira Kyrcz-Krzemien et al.
HEMATOLOGY (2016)
Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US
E. Jones et al.
BMC HEALTH SERVICES RESEARCH (2016)
Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation
Lucas C. M. Arruda et al.
CLINICAL IMMUNOLOGY (2016)
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L. Atkins et al.
LANCET (2016)
Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience
Daniela Curr et al.
NEUROLOGICAL SCIENCES (2016)
Cost of Illness of Multiple Sclerosis - A Systematic Review
Olivia Ernstsson et al.
PLOS ONE (2016)
Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives
Jury L. Shevchenko et al.
ANNALS OF HEMATOLOGY (2015)
Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis
Alessandra de Paula A. Sousa et al.
CLINICAL SCIENCE (2015)
A basic overview of multiple sclerosis immunopathology
N. Grigoriadis et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple Sclerosis
Richard K. Burt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study
Daniela Curro et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Aggressive multiple sclerosis: proposed definition and treatment algorithm
Carolina A. Rush et al.
NATURE REVIEWS NEUROLOGY (2015)
Effect of comorbidity on mortality in multiple sclerosis
Ruth Ann Marrie et al.
NEUROLOGY (2015)
Autologous hematopoietic stem cell transplantation in multiple sclerosis A phase II trial
Giovanni L. Mancardi et al.
NEUROLOGY (2015)
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) A 3-Year Interim Report
Richard A. Nash et al.
JAMA NEUROLOGY (2015)
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study
Daniela Curro et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Immunopathology of multiple sclerosis
Calliope A. Dendrou et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Hien K. Duong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data
Cathryn A. Carroll et al.
BMC HEALTH SERVICES RESEARCH (2014)
New Multiple Sclerosis Phenotypic Classification
Fred D. Lublin
EUROPEAN NEUROLOGY (2014)
T cell repertoire following autologous stem cell transplantation for multiple sclerosis
Paolo A. Muraro et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Joachim Burman et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
Paul Browne et al.
NEUROLOGY (2014)
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
Peter J. Darlington et al.
ANNALS OF NEUROLOGY (2013)
Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database
N. S. Majhail et al.
BONE MARROW TRANSPLANTATION (2013)
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis
Sofia V. Abrahamsson et al.
BRAIN (2013)
T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis
Joachim Burman et al.
IMMUNOLOGY (2013)
The cost burden of multiple sclerosis in the United States: a systematic review of the literature
Gabriel Adelman et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results
J. D. Bowen et al.
BONE MARROW TRANSPLANTATION (2012)
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
J. A. Snowden et al.
BONE MARROW TRANSPLANTATION (2012)
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance
Daniel M. Harrison et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience
G. L. Mancardi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper
R. Saccardi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Cost-effectiveness of disease-modifying therapy for multiple sclerosis A population-based study
K. Noyes et al.
NEUROLOGY (2011)
Age and disability accumulation in multiple sclerosis
A. Scalfari et al.
NEUROLOGY (2011)
High-Dose Cyclophosphamide Without Stem Cell Rescue in 207 Patients With Aplastic Anemia and Other Autoimmune Diseases
Amy E. DeZern et al.
MEDICINE (2011)
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis
P. Tappenden et al.
BONE MARROW TRANSPLANTATION (2010)
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
Antonio Scalfari et al.
BRAIN (2010)
The changing demographic pattern of multiple sclerosis epidemiology
Nils Koch-Henriksen et al.
LANCET NEUROLOGY (2010)
Multiple sclerosis genetics-is the glass half full, or half empty?
Jorge R. Oksenberg et al.
NATURE REVIEWS NEUROLOGY (2010)
High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors
Alessandro Re et al.
BLOOD (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
The natural history of primary progressive multiple sclerosis
Marcus Koch et al.
NEUROLOGY (2009)
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
Akiko M. Saito et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis
Edgar Meinl et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Temporal trends in the incidence of multiple sclerosis
Alvaro Alonso et al.
NEUROLOGY (2008)
Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies
B. J. Bolwell et al.
BONE MARROW TRANSPLANTATION (2007)
Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
A. M. Saito et al.
BONE MARROW TRANSPLANTATION (2007)
Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma
D. K. Hiwase et al.
CYTOTHERAPY (2007)
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
R. Saccardi et al.
MULTIPLE SCLEROSIS (2006)
G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: A possible mechanism for exacerbation of multiple sclerosis
O Snir et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis
JPA Samijn et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients
PA Muraro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Preclinical experiments
DW van Bekkum
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2004)
Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores
RK Burt et al.
BLOOD (2003)
Relapses and progression of disability in multiple sclerosis.
C Confavreux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor
H Openshaw et al.
NEUROLOGY (2000)
A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors
P Anderlini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
